Journal of Ophthalmic Inflammation and Infection

Table 5 Demographic data by institution (ITT)

From: Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients

			Gender				Age				Emery’s classification
			Male		Female		<65		≥65		1		2
			N	%	N	%	N	%	N	%	N	%	N	%
Total		Nepafenac	49	46.2	57	53.8	24	22.6	82	77.4	28	26.4	78	73.6
Total		Placebo	49	46.7	56	53.3	35	33.3	70	66.7	22	21.0	83	79.0
Investigator no.	1	Nepafenac	4	66.7	2	33.3	2	33.3	4	66.7	4	66.7	2	33.3
	1	Placebo	2	33.3	4	66.7	3	50.0	3	50.0	5	83.3	1	16.7
	2	Nepafenac	5	41.7	7	58.3	3	25.0	9	75.0	5	41.7	7	58.3
	2	Placebo	6	50.0	6	50.0	1	8.3	11	91.7	5	41.7	7	58.3
	3	Nepafenac	5	33.3	10	66.7	2	13.3	13	86.7	0	0.0	15	100.0
	3	Placebo	6	40.0	9	60.0	2	13.3	13	86.7	0	0.0	15	100.0
	4	Nepafenac	6	75.0	2	25.0	0	0.0	8	100.0	6	75.0	2	25.0
	4	Placebo	4	50.0	4	50.0	2	25.0	6	75.0	5	62.5	3	37.5
	5	Nepafenac	7	43.8	9	56.3	2	12.5	14	87.5	0	0.0	16	100.0
	5	Placebo	7	43.8	9	56.3	5	31.3	11	68.8	0	0.0	16	100.0
	6	Nepafenac	3	60.0	2	40.0	1	20.0	4	80.0	0	0.0	5	100.0
	6	Placebo	2	33.3	4	66.7	3	50.0	3	50.0	0	0.0	6	100.0
	7	Nepafenac	2	22.2	7	77.8	2	22.2	7	77.8	2	22.2	7	77.8
	7	Placebo	3	50.0	3	50.0	2	33.3	4	66.7	2	33.3	4	66.7
	8	Nepafenac	3	37.5	5	62.5	3	37.5	5	62.5	2	25.0	6	75.0
	8	Placebo	4	44.4	5	55.6	4	44.4	5	55.6	1	11.1	8	88.9
	9	Nepafenac	5	55.6	4	44.4	2	22.2	7	77.8	2	22.2	7	77.8
	9	Placebo	5	55.6	4	44.4	5	55.6	4	44.4	2	22.2	7	77.8
	10	Nepafenac	4	33.3	8	66.7	3	25.0	9	75.0	6	50.0	6	50.0
	10	Placebo	6	50.0	6	50.0	5	41.7	7	58.3	1	8.3	11	91.7
	11	Nepafenac	5	83.3	1	16.7	4	66.7	2	33.3	1	16.7	5	83.3
	11	Placebo	4	66.7	2	33.3	3	50.0	3	50.0	1	16.7	5	83.3

Back to article page